Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Losartan Effects on Emphysema Progression
NCT02696564 · View on ClinicalTrials.gov ↗
Study Summary
A randomized, parallel, placebo controlled trial to evaluate the effect of 100mg/day losartan on the progression of emphysema as measured by quantitative HRCT compared to placebo .
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Losartan
Study Locations (20)
Illinois
- University of Illinois at Chicago — Chicago
- Northwestern University — Chicago
- Rush University Medical Center — Chicago
- University of Chicago Hospitals — Chicago
California
- University of California at San Diego — San Diego
- University of California at San Francisco — San Francisco
Florida
- University of Florida College of Medicine — Jacksonville
- University of South Florida — Tampa
Missouri
- St. Louis University School of Medicine — St Louis
- St. Louis Asthma Clinical Research Center - Washington University School of Medicine — St Louis
New York
- New York University School of Medicine — New York
- Weill Cornell Medicine — New York
Alabama
- University of Alabama at Birmingham — Birmingham
Arizona
- University of Arizona — Tucson
Colorado
- National Jewish Medical and Research Center — Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2017-05-23 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02696564
The ClinicalTrials.gov registry entry for NCT02696564 describes a study currently listed as completed. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is JHSPH Center for Clinical Trials, which has 7 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Emphysema appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02696564 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Illinois, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02696564 about?
NCT02696564 is a clinical study titled "Losartan Effects on Emphysema Progression". A randomized, parallel, placebo controlled trial to evaluate the effect of 100mg/day losartan on the progression of emphysema as measured by quantitative HRCT compared to placebo .
What is the current status of trial NCT02696564?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 220 participants. The study started on 2017-05-23. Estimated completion is 2021-06-30.
What conditions does trial NCT02696564 study?
This clinical trial studies the following conditions: Emphysema. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02696564?
The interventions under investigation include: Placebo (DRUG), Losartan (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02696564?
This trial is sponsored by JHSPH Center for Clinical Trials, which has 7 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02696564 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.